Navigation Links
deCODE genetics Announces Third Quarter 2007 Financial Results
Date:11/5/2007

REYKJAVIK, Iceland, Nov. 5 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended September 30, 2007. A conference call to discuss the quarter's results and recent operating highlights will be webcast live tomorrow, Tuesday, November 6, at 8:00am Eastern Standard Time/1pm GMT (details below).

Net loss for the quarter ending September 30, 2007 was $24.2 million, compared to $23.6 million for the third quarter 2006. Net loss for the first nine months of 2007 was $63.1 million, compared to $62.2 million for the first nine months of last year. Basic and diluted net loss per share was $0.40 for the third quarter 2007, unchanged from the same period last year. For the first nine months of 2007, basic and diluted net loss per share was $1.03, compared to $1.11 for the first nine months of last year. At the close of the third quarter 2007, the company had approximately 61.7 million shares outstanding.

Revenue for the third quarter this year was $10.9 million, compared to $8.6 million for the same period a year ago. For the first nine months of 2007, revenue was $27.1 million, compared to $29.1 million for the same period last year. As of September 30, 2007, the company had $15.2 million in deferred revenue that will be recognized over future reporting periods. The largest single factor in the period-on-period increase in revenue for the third quarter, and in the company's deferred revenue, is the growth of the company's genotyping business.

Research and development expense was $14.1 million for the third quarter of this year, compared to $14.2 million for the same period last year. For the first nine months of 2007, R&D expense was $4
'/>"/>

SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...r 19 MONITORING FORCE GmbH,announc...banserin in the,indication treatment-relevant levo... orphan drug status designation with the European ...ia is a complication of the mainstay,treatment in ...of those,affected, since it may be disabling for t...
(Date:11/19/2009)...r 19 AFFiRiS AG will focus its,Alz...at an unexpectedly early,stage of development: the...hase II clinical trial early in 2010. This decisio...n of two Phase I trials with the candidates,AD01 a...e first interim,analysis of the secondary endpoint...
(Date:11/18/2009)...are developing new sensors to detect chemical agen...against the threat of terrorist attacks. , The d...ividual or crime scene to gather a sample which is...etect the presence of chemicals within seconds. Th...in response to terrorist threats. , The scannin...
(Date:11/18/2009)...re/ -- Reportlinker.com announces that a new marke..., Biotechnology Reagents - A Global Market Pe...164375/Biotechnology-Reagents---A-Global-Market-Pe...m=pr&utm_campaign=prnewswire ,, Reagents ...ds used in a range of biotech related areas includ...
Breaking Biology Technology:MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3New technology detects chemical weapons in seconds 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 3Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 4Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 5Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 6Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 7Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 8
...RATON, Fla., March 13 JAG Media Holdings, Inc. (O...as entered into a letter of intent with CardioGeni... which CardioGenics will be acquired by JAG Media ... Inc., an Ontario, Canada corporation wholly-owned...nada corporation that will be wholly-owned by JAG ...
...LE, March 13 /PRNewswire-FirstCall/ - Oncothyreon ...company specializing in the development of innovat...er, today announced that Robert Kirkman, M.D., Pre...t the Invest Northwest 2009 Conference at 9:40 a.m...ive and archived webcast of Dr. Kirkman,s presenta...
..., N.J., March 13 /PRNewswire-FirstCall/ -- DOR B...the Company) announced today that it has appointed...ent and Chief Medical Officer. Dr. Hamilton is a r... topically active steroids as well as in Graft-ver...tinguished career of more than 25 years in both ac...
Other Biology Technology:JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media 2JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media 3DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 2DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 3DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 4DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer 5
(Date:11/19/2009)...ize has identified thousands of diverse genes in g...w techniques may allow breeders and researchers to...traits and create new varieties that were not easi...issue of Science , the researchers, whose senior ...he first map of haplotypes sets of closely linked...
(Date:11/19/2009)...etitive NIH Director,s T-R01 Award , Speedier Lab.... Samie Jaffrey, associate professor of pharmacolo...first researchers to win a prestigious NIH Directo...titutes of Health. Dr. Jaffrey and his colleagues ...nologies that may some day speed up lab testing by...
(Date:11/19/2009)...lingly consume a highly endangered species, doing ... box. New genetic detective work from the Sackler ... Museum of Natural History shows that bluefin tuna...York and Colorado. A quarter of what was labeled a...en escolar, a waxy, buttery fish often labeled "wh...
Breaking Biology News(10 mins):New map of variation in maize genetics holds promise for developing new varieties 2Weill Cornell science briefs: November 2009 2Weill Cornell science briefs: November 2009 3Weill Cornell science briefs: November 2009 4Weill Cornell science briefs: November 2009 5Unknowlingly consuming endangered tuna 2Unknowlingly consuming endangered tuna 3OriGene Technologies Acquires Marligen Biosciences 14527 1OriGene Technologies Acquires Marligen Biosciences 14527 2Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2 2009 5572 1Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 5568 1Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 5568 2Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 5568 3Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 5568 4Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009 5568 5
...n international team that included scientists from...RI), part of the National Institutes of Health (NI...tic variants involved in type 2 diabetes, boosting...sociated with increased risk of the disease. None ... had previously been suspected of playing a role i...
...sing an important new method that can be applied i...ists at Cold Spring Harbor Laboratory (CSHL) in co...ashington (UW) and the National Institute of Menta...ually rare gene mutations in people with schizophr...lness is caused. , The team screened for novel ...
...aleigh, NC, March 28, 2008 - The American Diabetes...diology (ACC) issued a consensus statement today t...by nuclear magnetic resonance (NMR) is one of the ...k (CMR). The study, published in the April issue ...may not be the best way to quantify a patients ris...
Other Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia 2CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia 3LDL particle measurement by NMR recognized by ADA, ACC 2
BAKERBOND WP PEI(CH2CH2NH) 15\um Prep HPLC Column from J.T. Baker
Mouse Anti-Nestin, Human Monoclonal Antibody, Unconjugated, Clone 10C2 from CHEMICON
Rabbit Anti-NFkB p105 / p50, phospho (Ser529) Antibody, Unconjugated from Raybiotech, Inc.
Rabbit Anti-Mouse C-10 (CC Chemokine) Antibody, Biotin Conjugated from CEDARLANE Laboratories Limited
Biology Products: